Fagron

Fagron ROE

The Return on Equity (ROE) of Fagron (FAGR.BR) as of Nov 3, 2026 is 16.50 %. In the previous year, Return on Equity (ROE) was 16.07 % — a change of 2.70% (higher).

ROE

16.50 %

YoY

2.70%

Last updated:

In 2025, Fagron's return on equity (ROE) was 16.50 %, a 2.70% increase from the 16.07 % ROE in the previous year.

The Fagron ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
20.64 EUR
Jan 1, 2019
23.01 EUR
Jan 1, 2020
23.55 EUR
Jan 1, 2021
19.06 EUR
Jan 1, 2022
17.29 EUR
Jan 1, 2023
15.21 EUR
Jan 1, 2024
16.07 EUR
Jan 1, 2025
16.50 EUR
The Fagron ROE history
YEARROEYoY
16.50 %+2.70%
16.07 %+5.61%
15.21 %-12.01%
17.29 %-9.28%
19.06 %-19.07%
23.55 %+2.34%
23.01 %+11.47%
20.64 %-19.75%
25.72 %-287.38%
-13.73 %-104.58%
299.86 %+2,757.53%
10.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fagron Stock analysis

What does Fagron do? Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron is one of the most popular companies on Eulerpool.

ROE Details

Decoding Fagron's Return on Equity (ROE)

Fagron's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Fagron's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Fagron's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Fagron’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Fagron stock

Return on Equity (ROE) of Fagron is 16.50 % in 2025.

Return on Equity (ROE) of Fagron changed from 16.07 % to 16.50 %, representing a 2.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Fagron since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Fagron with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Fagron

All Key Metrics — Fagron